FDA grants Alpheus Medical orphan drug and fast track designations for novel sonodynamic therapy for brain cancer

Alpheus Medical

13 July 2022 - The company is currently enrolling patients in a multicentre Phase 1 clinical trial for the treatment of recurrent glioblastoma.

Alpheus Medical today announced the U.S. FDA has granted both orphan drug and fast track designations to Alpheus Medical's CV-01 delivery of sonodynamic therapy as a potential treatment for patients with recurrent glioblastoma, the most common primary brain cancer, and other malignant gliomas.

Read Alpheus Medical press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , US , Fast track